Eli Lilly's 340B Termination Turns Into Litigation and Congressional Pushback — Tampa General Sues in Federal Court, 72 House Members Demand HHS Act

Eli Lilly's June 1 five-day ultimatum escalated on June 18, 2026, when the manufacturer cut off 340B pricing for covered entities that refused to share in-house pharmacy claims data — Lilly directed wholesaler McKesson to end Tampa General Hospital's discounts after it missed the deadline, per the hospital's complaint. Tampa General sued Lilly on July 2 in the U.S. District Court for the Middle District of Florida, alleging the cutoff raised its average costs for Lilly medications 25-50% — losses the complaint pegs at roughly $24.7 million a year, including a 35.9% jump on Mounjaro.

Separately, 72 bipartisan U.S. House members — led by Reps. Doris Matsui (D-CA) and Jack Bergman (R-MI) — signed an early-July letter to HHS Secretary Kennedy and HRSA Administrator Engels urging use of 'any enforcement mechanisms available' against Lilly's move and restoration of 340B pricing.

Coverage so far documents hospitals as the entities cut off; no health-center termination has been confirmed, but FQHCs dispensing Lilly products face the same claims-data condition documented in the June 1 ultimatum item and should confirm their data-sharing posture now.